Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Ratio (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Equity Ratio for 13 consecutive years, with 0.56 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 7.43% to 0.56 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.56, a 7.43% increase, with the full-year FY2024 number at 0.5, changed N/A from a year prior.
  • Equity Ratio was 0.56 for Q3 2025 at Theravance Biopharma, up from 0.53 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.73 in Q4 2022 to a low of 0.99 in Q1 2021.
  • A 5-year average of 0.15 and a median of 0.53 in 2025 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: plummeted 281.39% in 2021, then surged 178.41% in 2022.
  • Theravance Biopharma's Equity Ratio stood at 0.8 in 2021, then surged by 190.61% to 0.73 in 2022, then dropped by 18.18% to 0.6 in 2023, then dropped by 16.71% to 0.5 in 2024, then rose by 12.99% to 0.56 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Equity Ratio are 0.56 (Q3 2025), 0.53 (Q2 2025), and 0.48 (Q1 2025).